Stockscreener 앱 받기
53.51
1.29%
-0.70
전일 마감가:
$54.21
열려 있는:
$54.15
하루 거래량:
1.39M
Relative Volume:
0.68
시가총액:
$5.10B
수익:
$170.10M
순이익/손실:
$-239.59M
주가수익비율:
-19.11
EPS:
-2.8
순현금흐름:
$-191.20M
1주 성능:
-0.61%
1개월 성능:
-4.40%
6개월 성능:
-2.96%
1년 성능:
+32.78%
1일 변동 폭
$53.10
$54.75
1주일 범위
$53.10
$57.99
52주 변동 폭
$30.04
$78.48
크리스퍼 테라퓨틱스 Stock (CRSP) Company Profile
명칭
Crispr Therapeutics Ag
전화
(617) 315-4600
주소
BAARERSTRASSE 14, ZUG
CRSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
53.51 | 5.17B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
크리스퍼 테라퓨틱스 Stock (CRSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-18 | 개시 | JP Morgan | Overweight |
| 2025-02-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-02-12 | 업그레이드 | TD Cowen | Sell → Hold |
| 2025-02-03 | 개시 | H.C. Wainwright | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-08-02 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-28 | 재개 | Guggenheim | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-11 | 다운그레이드 | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 개시 | Mizuho | Buy |
| 2023-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-04-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2023-03-07 | 개시 | Robert W. Baird | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-08-09 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-04-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-10 | 재확인 | Chardan Capital Markets | Buy |
| 2020-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-10 | 재확인 | Needham | Buy |
| 2020-12-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-07-28 | 재확인 | Needham | Buy |
| 2020-07-14 | 개시 | SunTrust | Buy |
| 2020-06-15 | 재확인 | Canaccord Genuity | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-19 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 개시 | Jefferies | Buy |
| 2019-07-26 | 개시 | Canaccord Genuity | Buy |
| 2019-06-10 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-14 | 개시 | William Blair | Mkt Perform |
| 2019-01-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
모두보기
크리스퍼 테라퓨틱스 주식(CRSP)의 최신 뉴스
Meme Stocks: Will CRISPR Therapeutics AG benefit from geopolitical trendsJuly 2025 Selloffs & AI Powered Market Entry Ideas - baoquankhu1.vn
Price Action: Is CRISPR Therapeutics AG showing insider buyingJuly 2025 Market Mood & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Radnet (RDNT) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Nwam LLC Purchases 83,454 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Crispr Therapeutics AG (CRSP) Gets a Buy from Bank of America Securities - The Globe and Mail
CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Aug Summary: Can CRISPR Therapeutics AG maintain its current growth rateEarnings Risk Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
A Look At CRISPR Therapeutics (CRSP) Valuation As 2026 Gene Editing Milestones Come Into Focus - Sahm
Is CRISPR Therapeutics (CRSP) Using J.P. Morgan Spotlight to Recast Its Gene-Editing Leadership Story? - Sahm
CRISPR Therapeutics: Patience And Opportunity Through Volatility (NASDAQ:CRSP) - Seeking Alpha
Sumitomo Mitsui Trust Group Inc. Sells 251,163 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - sharewise.com
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and NeoGenomics (NEO) - The Globe and Mail
Investors heavily search CRISPR Therapeutics AG (CRSP): Here is what you need to know - MSN
What's Driving the Market Sentiment Around CRISPR Therapeutics AG? - Benzinga
CRSP: Casgevy and next-gen gene editing platforms drive growth, with 2026 set as a pivotal year - TradingView — Track All Markets
2 Biotech Stocks That Could Soar This Year - Finviz
CRISPR Therapeutics (CRSP) Is Considered a Good Investment by Brokers: Is That True? - Finviz
CRSP: Regulatory Submissions for CASGEVY Expected by Mid-2026 - GuruFocus
CRSP Outlines Strategic Goals and Milestones for 2026 - GuruFocus
CRISPR Therapeutics Highlights Pipeline Advances in Gene-Edited Therapies - TipRanks
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones - The Manila Times
CRISPR Therapeutics Highlights Program Advancements - TradingView — Track All Markets
CRISPR Therapeutics stock (CRSP) drops into JPM week — what to watch next - TechStock²
CRISPR Therapeutics Reports Q3 2025 Financial Results - MSN
Avoiding Lag: Real-Time Signals in (CRSP) Movement - Stock Traders Daily
Is CRISPR Therapeutics (CRSP) Attractive After Recent Gene Editing Progress And Mixed Returns? - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - sharewise.com
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next - TechStock²
Revenue Check: How CRISPR Therapeutics AG stock valuations compare to rivalsStop Loss & Detailed Earnings Play Strategies - moha.gov.vn
Quarterly Risk: Is CRISPR Therapeutics AG stock a contrarian buyJuly 2025 Setups & Community Verified Watchlist Alerts - ulpravda.ru
Can CRISPR Therapeutics AG stock beat market expectations this quarterTreasury Yields & Real-Time Market Sentiment Reports - ulpravda.ru
Why global investors buy CRISPR Therapeutics AG (1CG) stock2025 Technical Patterns & Real-Time Market Sentiment Reports - ulpravda.ru
CRISPR Therapeutics AG CFO Sells Shares Under Trading Plan - TradingView — Track All Markets
Institutional Investors Are CRISPR Therapeutics AG's (NASDAQ:CRSP) Biggest Bettors and Were Rewarded After Last Week's US$529m Market Cap Gain - 富途牛牛
Is CRISPR Therapeutics AG stock positioned for long term growthVolatility Index Analysis & Free Discover Dynamic Stocks - ulpravda.ru
Aug Outlook: Why CRISPR Therapeutics AG (1CG) stock could be next leaderQuarterly Trade Report & Capital Efficient Trading Techniques - moha.gov.vn
Is CRISPR Therapeutics (CRSP) Attractively Priced After Recent Gene Editing Progress? - simplywall.st
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why - sharewise.com
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 8.7%Still a Buy? - MarketBeat
Chardan maintains a buy recommendation on CRISPR Therapeutics AG (CRSP) - MSN
Why CRISPR Therapeutics (CRSP) Soared on Friday? - MSN
CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Assessing CRISPR Therapeutics (CRSP) Valuation As Investor Interest Returns - simplywall.st
Assessing CRISPR Therapeutics' (CRSP) Valuation After Recent Share Price Volatility - Yahoo Finance
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize - Benzinga
Crispr Therapeutics: Prospects For 2026Why I Believe Casgevy Is Key (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics AG Stock Analysis and ForecastInsider Trading Compliance & Unlock Free Weekly Portfolio Checkups - earlytimes.in
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next - TechStock²
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
크리스퍼 테라퓨틱스 (CRSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
크리스퍼 테라퓨틱스 주식 (CRSP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Prasad Raju | Chief Financial Officer |
Jan 06 '26 |
Sale |
60.16 |
29,700 |
1,786,636 |
6,767 |
4.73%
0.92%
자본화:
|
볼륨(24시간):